{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T21:22:40Z","timestamp":1785014560585,"version":"3.55.0"},"reference-count":46,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T00:00:00Z","timestamp":1682640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Background: Treatment of hidradenitis suppurativa (HS) is difficult and current guidelines are based mainly on expert opinion and non-randomized controlled trials. Recently, there have been some targeted therapies using uniform primary endpoints for outcome assessment. Objective: Recommendations can be provided on selecting biologics and targeted synthetic small molecules for refractory HS by comparing the efficacy and safety of these medications. Methods: Databases including ClinicalTrial.gov, Cochrane Library, and PubMed were searched. Randomized controlled trials (RCTs) for moderate-to-severe HS were eligible. We performed random-effect network meta-analysis and ranking probability. The primary outcome was Hidradenitis Suppurativa Clinical Response (HiSCR) at 12\u201316 weeks. Secondary outcome included Dermatology Life Quality Index (DLQI) 0\/1, mean change of DLQI from baseline, and adverse effects. Results: A total of 12 RCTs involving 2915 patients were identified. Adalimumab, bimekizumab, secukinumab 300 mg q4w and secukinumab 300 mg q2w showed superiority to placebo in HiSCR at weeks 12 to 16. In addition, there was no significant difference between bimekizumab and adalimumab as measured by HiSCR (RR = 1.00; 95% CI: 0.66\u20131.52) and DLQI 0\/1 (RR = 2.40, 95% CI: 0.88\u20136.50). In terms of ranking probability for achieving HiSCR at 12\u201316 weeks, adalimumab ranked first, followed by bimekizumab, secukinumab 300 mg q4w, and secukinumab 300 mg q2w. All biologics and small molecules did not differ in the development of adverse effects compared to placebo. Conclusions: Adalimumab, bimekizumab, secukinumab 300 mg q4w and secukinumab 300 mg q2w represent four regimens that produce better outcomes than placebo without increased risk of adverse events. Adalimumab and bimekizumab exhibited best HiSCR and DLQI 0\/1 between weeks 12\u201316.<\/jats:p>","DOI":"10.3390\/pharmaceutics15051351","type":"journal-article","created":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T04:36:15Z","timestamp":1682656575000},"page":"1351","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Efficacy and Safety of Biologics and Small Molecules for Moderate-to-Severe Hidradenitis Suppurativa: A Systematic Review and Network Meta-Analysis"],"prefix":"10.3390","volume":"15","author":[{"given":"Ya-Chu","family":"Tsai","sequence":"first","affiliation":[{"name":"Department of Dermatology, Far Eastern Memorial Hospital, New Taipei 220, Taiwan"},{"name":"Department of Fashion Styling and Design, Minghsin University of Science and Technology, Hsinchu 30401, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Yiu","family":"Hung","sequence":"additional","affiliation":[{"name":"Department of Thoracic Medicine, Chang Gung University College of Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan 333, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1498-1474","authenticated-orcid":false,"given":"Tsen-Fang","family":"Tsai","sequence":"additional","affiliation":[{"name":"Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei 100, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,4,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41572-020-0149-1","article-title":"Hidradenitis suppurativa","volume":"6","author":"Sabat","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1001\/jamadermatol.2021.1677","article-title":"Prevalence of hidradenitis suppurativa: A systematic review and meta-regression analysis","volume":"157","author":"Jfri","year":"2021","journal-title":"JAMA Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/jdv.16677","article-title":"Hidradenitis suppurativa: An update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life","volume":"35","author":"Nguyen","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jaad.2019.08.090","article-title":"Hidradenitis suppurativa: Epidemiology, clinical presentation, and pathogenesis","volume":"82","author":"Goldburg","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.jaad.2021.01.059","article-title":"Comorbidity screening in hidradenitis suppurativa: Evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations","volume":"86","author":"Garg","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/jdv.15233","article-title":"Hidradenitis suppurativa\/acne inversa: A practical framework for treatment optimization\u2013systematic review and recommendations from the HS ALLIANCE working group","volume":"33","author":"Zouboulis","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1033844","DOI":"10.3389\/fimmu.2022.1033844","article-title":"Risk of psoriasis in people with hidradenitis suppurativa: A systematic review and meta-analysis","volume":"13","author":"Gau","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1097\/DSS.0000000000001916","article-title":"Defining fistular patterns in hidradenitis suppurativa: Impact on the management","volume":"45","author":"Martorell","year":"2019","journal-title":"Dermatol. Surg."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.jaad.2018.11.035","article-title":"Clindamycin versus clindamycin plus rifampicin in hidradenitis suppurativa treatment: Clinical and ultrasound observations","volume":"80","author":"Caro","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e14706","DOI":"10.1111\/dth.14706","article-title":"Vascularization and fibrosis are important ultrasonographic tools for assessing response to adalimumab in hidradenitis suppurativa: Prospective study of 32 patients","volume":"34","author":"Nazzaro","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1177\/1203475419852049","article-title":"Hidradenitis suppurativa: Comprehensive review of predisposing genetic mutations and changes","volume":"23","author":"Jfri","year":"2019","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Moltrasio, C., Tricarico, P.M., Romagnuolo, M., Marzano, A.V., and Crovella, S. (2022). Hidradenitis suppurativa: A perspective on genetic factors involved in the disease. Biomedicines, 10.","DOI":"10.3390\/biomedicines10082039"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/bjd.18983","article-title":"Evidence for a \u2018window of opportunity\u2019in hidradenitis suppurativa treated with adalimumab: A retrospective, real-life multicentre cohort study","volume":"184","author":"Marzano","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1007\/s40265-021-01566-2","article-title":"Clinical implementation of biologics and small molecules in the treatment of hidradenitis suppurativa","volume":"81","author":"Aarts","year":"2021","journal-title":"Drugs"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"\u015awierczewska, Z., Lewandowski, M., Surowiecka, A., and Bara\u0144ska-Rybak, W. (2022). Immunomodulatory Drugs in the Treatment of Hidradenitis Suppurativa\u2014Possibilities and Limitations. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23179716"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"20406223211055920","DOI":"10.1177\/20406223211055920","article-title":"New perspectives on the treatment of hidradenitis suppurativa","volume":"12","author":"Vilarrasa","year":"2021","journal-title":"Ther. Adv. Chronic Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: Checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"ref_19","unstructured":"Huang, W.M., Lin, S.H., and Liu, J.W. (2021, August 31). ShinyNMA. Available online: https:\/\/jerryljw.shinyapps.io\/ShinyNMA_\/."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two phase 3 trials of adalimumab for hidradenitis suppurativa","volume":"375","author":"Kimball","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/jdv.13216","article-title":"HiSCR (Hidradenitis Suppurativa Clinical Response): A novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study","volume":"30","author":"Kimball","year":"2016","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"846","DOI":"10.7326\/0003-4819-157-12-201212180-00004","article-title":"Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: A parallel randomized trial","volume":"157","author":"Kimball","year":"2012","journal-title":"Ann. Intern. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1001\/jamasurg.2021.3655","article-title":"Efficacy and safety of adalimumab in conjunction with surgery in moderate to severe hidradenitis suppurativa: The SHARPS randomized clinical trial","volume":"156","author":"Bechara","year":"2021","journal-title":"JAMA Surg."},{"key":"ref_25","unstructured":"Kimball, A.B., Alavi, A., Jemec, G.B., Gottlieb, A., Wei, X., Wozniak, M.B., Uhlmann, L., Martinez, A.L., Keefe, D., and Martin, R. (2022, January 7\u201310). Secukinumab in moderate to severe hidradenitis suppurativa: Primary endpoint analysis from the SUNSHINE and SUNRISE Phase 3 trials. Proceedings of the 31st European Academy of Dermatology and Venereology (EADV) Congress, Milan, Italy."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1001\/jamadermatol.2021.2905","article-title":"Efficacy and safety of bimekizumab in moderate to severe hidradenitis suppurativa: A phase 2, double-blind, placebo-controlled randomized clinical trial","volume":"157","author":"Glatt","year":"2021","journal-title":"JAMA Dermatol."},{"key":"ref_27","unstructured":"(2023, January 03). A Global Study Comparing Risankizumab to Placebo in Adult Participants with Moderate to Severe Hidradenitis Suppurativa (DETERMINED 1), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT03926169?term=risankizumab&cond=Hidradenitis+Suppurativa&draw=2&rank=1."},{"key":"ref_28","unstructured":"(2023, January 03). A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants with Moderate to Severe Hidradenitis Suppurativa (HS) (NOVA), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03628924?term=guselkumab&cond=Hidradenitis+Suppurativa&draw=2&rank=3."},{"key":"ref_29","unstructured":"(2023, January 03). Efficacy and Safety Study of IFX-1 in Patients with Moderate to Severe Hidradenitis Suppurativa (HS) (SHINE), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03487276?term=IFX-1&cond=Hidradenitis+Suppurativa&draw=2&rank=1."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"B19","DOI":"10.1016\/j.jid.2021.07.121","article-title":"Avacopan, a highly selective small molecule inhibitor of c5a receptor, in patients with Hidradenitis Suppurativa: Initial results from a randomized, double-blind, placebo-controlled, phase 2 study (aurora)","volume":"141","author":"Kirby","year":"2021","journal-title":"J. Investig. Dermatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1111\/exd.14619","article-title":"IL-17A is a pertinent therapeutic target for moderate-to-severe hidradenitis suppurativa: Combined results from a pre-clinical and phase II proof-of-concept study","volume":"31","author":"Kimball","year":"2022","journal-title":"Exp. Dermatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/bjd.19556","article-title":"Aetiology and pathogenesis of hidradenitis suppurativa","volume":"183","author":"Wolk","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Markota \u010cagalj, A., Marinovi\u0107, B., and Bukvi\u0107 Mokos, Z. (2022). New and emerging targeted therapies for hidradenitis suppurativa. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23073753"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jaad.2009.06.050","article-title":"Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: A randomized, double-blind, placebo-controlled crossover trial","volume":"62","author":"Grant","year":"2010","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1001\/archdermatol.2010.72","article-title":"Treatment of hidradenitis suppurativa with etanercept injection","volume":"146","author":"Adams","year":"2010","journal-title":"Arch. Dermatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1001\/jamadermatol.2015.3903","article-title":"Safety and efficacy of anakinra in severe hidradenitis suppurativa: A randomized clinical trial","volume":"152","author":"Tzanetakou","year":"2016","journal-title":"JAMA Dermatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jid.2017.10.030","article-title":"MABp1 targeting IL-1\u03b1 for moderate to severe hidradenitis suppurativa not eligible for adalimumab: A randomized study","volume":"138","author":"Kanni","year":"2018","journal-title":"J. Investig. Dermatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jaad.2018.06.046","article-title":"Apremilast for moderate hidradenitis suppurativa: Results of a randomized controlled trial","volume":"80","author":"Vossen","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/bjd.20969","article-title":"Janus kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa: Results from two phase II studies","volume":"186","author":"Alavi","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/bjd.14475","article-title":"Development of core outcome sets in hidradenitis suppurativa: Systematic review of outcome measure instruments to inform the process","volume":"175","author":"Ingram","year":"2016","journal-title":"Br. J. Dermatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1111\/bjd.13270","article-title":"Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment","volume":"171","author":"Kimball","year":"2014","journal-title":"Br. J. Dermatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1080\/09546634.2021.1927949","article-title":"Efficacy of non-surgical monotherapies for hidradenitis suppurativa: A systematic review and network meta-analyses of randomized trials","volume":"33","author":"Gupta","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/art.40759","article-title":"Ustekinumab fails to show efficacy in a Phase III axial spondyloarthritis program: The importance of negative results","volume":"71","author":"Mease","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/art.40728","article-title":"Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Huang, C.H., Huang, I.H., Tai, C.C., and Chi, C.C. (2022). Biologics and small molecule inhibitors for treating hidradenitis suppurativa: A systematic review and meta-analysis. Biomedicines, 10.","DOI":"10.3390\/biomedicines10061303"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/ced.14448","article-title":"Dermal tunnels influence time to clinical response and family history influences time to loss of clinical response in patients with hidradenitis suppurativa treated with adalimumab","volume":"46","author":"Frew","year":"2021","journal-title":"Clin. Exp. Dermatol."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/15\/5\/1351\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:25:19Z","timestamp":1760124319000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/15\/5\/1351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,28]]},"references-count":46,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["pharmaceutics15051351"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics15051351","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,28]]}}}